Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Bradpalm1 who wrote (6374)	11/27/1998 6:41:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Top ten global companies by market value LONDON, Nov 26 (Reuters) - A merger of Exxon Corp <XON.N>, and Mobil Corp <MOB.N>, if completed, would create the world's third largest listed company in terms of market capitalisation, according to data from Reuters Securities 3000. Reports that Exxon, the world's largest energy company and Mobil, the second biggest oil group in the U.S., were in merger talks sent Mobil's share price up nearly five percent on Wednesday, valuing Mobil at $58.44 billion. TOP TEN GLOBAL COMPANIES IN TERMS OF MARKET CAPITALISATION Company RIC Market cap($bln) 1. General Electric <GE.N> $305.179 bln 2. Microsoft Corp <MSFT.O> $302.523 bln 3. Exxon/Mobil<XON.N><MOB.N> $237.526 bln 4. Merck & Co Inc <MRK.N> $189.930 bln 5. Coca Cola Inc <KO.N> $181.316 bln 6. Intel Corp <INTC.O> $179.551 bln 7. Wal-Mart Stores <WMT.N> $170.688 bln 8. IBM Corp <IBM.N> $161.993 bln 9. Shell <RD.AS><SHEL.L> $160.797 bln 10.Pfizer Inc <PFE.N> $147.921 bln (Based on closing share prices on Wednesday, 25 November. SOURCE: Reuters Securities 3000).

To: Bradpalm1 who wrote (6374)	11/30/1998 10:46:00 AM
From: Tunica Albuginea	Read Replies (2) \| Respond to of 9523

Braddy, I covered my short this AM @ 113 ¼ for a 0.5 point < GG >short term profit. Not as much as I had hoped for; people still seem mesmerized by the $$$ signs in front of Viagra and are holding on to the stock, gg. Not to worry however, just getting warmed up here, GG. Can't wait for the Celebrex pop to get back in: "But detailed clinical data on Celebrex has not yet been published, and some researchers still have concerns about COX-2 drugs. "I will predict these won't be safer in patients with intrinsic kidney disease," Harvard's Simon said. "https://www.siliconinvestor.com/readmsg.aspx?msgid=6586650 << GGG >> Well, well, well,……….what do we have here, " detailed clinical data on Celebrex has not yet been published ". Reeally ? Kidney side effects? Other? Side effects? And more, "With treatment expected to cost $2-$4 a day, Zisson thinks first year sales may hit $300-400 million, but final estimates will depend on whether health insurers decide on strict limits for who gets the new drugs, according to Zisson." Another expensive drug? Another Viagra in the making? GG Prostaglandins are the body's natural vasodilators. Celebrex by inhibiting them will cause a generalized circulatory vasoconstriction and cut perfusion to vital organs. NSAIDs already do this and knock the kidney for a loop. ( Over the counter non-steroidals have been a boon to nephrologists ). I am ready Braddy to short PFE again on it's next move up, GG. Of course if the FDA puts the brakes on Celebrex this week we'll immediately short just as fast as on it's way up, Tuna, a hard working doc just trying to make a couple of extra bucks